United States
Premiumsupplier
Cadazolid CAS NO.1025097-10-2
- Min.Order: 1 Gram
- Payment Terms: L/C
- Product Details
Keywords
- 1025097-10-2
- cas1025097-10-2
- 3-?Quinolinecarboxylic acid, 1-?cyclopropyl-?6-?fluoro-?7-?[4-?[[2-?fluoro-?4-?[(5R)?-?5-?(hydroxymethyl)?-?2-?oxo-?3-?oxazolidinyl]?phenoxy]?methyl]?-?4-?hydroxy-?1-?piperidinyl]?-?1,?4-?dihydro-?4-?
Quick Details
- ProName: Cadazolid
- CasNo: 1025097-10-2
- Molecular Formula: C29H29F2N3O8
- Application: Cadazolid is an experimental antibioti...
- DeliveryTime: 7 days
- PackAge: inquiry
- Port: inquiry
- ProductionCapacity: 10 Kilogram/Month
- Purity: > 95%
- Transportation: inquiry
- LimitNum: 1 Gram
Superiority
BOC Sciences is committed to supplying cost-effective products and services. We provide Cadazolid. Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly.Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug is in Phase III trials.The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores. More information please visit: www.bocsci.com/cadazolid-cas-1025097-10-2-item-467964.html
Details
BOC Sciences is committed to supplying cost-effective products and services. We provide Cadazolid. Cadazolid is an experimental antibiotic of the oxazolidinone class made by Actelion Pharmaceuticals Ltd. which is effective against Clostridium difficile, a major cause of drug resistant diarrhea in the elderly.Current drug treatments for this infection involve orally delivered antibiotics, principally fidaxomicin, metronidazole and vancomycin; the last two drugs are the principal therapeutic agents in use, but fail in approximately 20 to 45% of the cases. The drug is in Phase III trials.The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores. More information please visit: www.bocsci.com/cadazolid-cas-1025097-10-2-item-467964.html